Ingredients to watch in 2026
The nutraceutical world is doubling down on ashwagandha, colostrum, creatine and protein as 2026's top 'ingredients to watch' for product development and athlete/patient nutrition strategies (nutritionaloutlook.com). Industry analysts say these ingredients are driving R&D and commercialization this year (nutritionaloutlook.com).
Nutritional Outlook assembled its 2026 “Ingredients to Watch” using SPINS functional-ingredient sales drawn from mainstream multi-outlet and natural channels, and quoted SPINS senior director Scott Dicker on the slow, multi-year lifecycle of ingredient trends. (nutritionaloutlook.com) SPINS data singled out colostrum for “incredible sales performance” in the 52 weeks ending Nov. 30, 2025, driven by cross-category moves into beauty‑from‑within and longevity formats. (nutritionaloutlook.com) Retail rollouts illustrate that demand: ARMRA’s bovine colostrum launched in all 1,400 Ulta Beauty stores in July 2025, and direct‑to‑consumer and celebrity‑backed colostrum products from brands such as Lemme appeared in late 2025 and early 2026. (businesswire.com) Ashwagandha is hitting mainstream shelves as well — VAHDAM announced an Ashwagandha Coffee launch into roughly 1,000 Target stores beginning May 2026 — while market research groups estimate the global ashwagandha supplements category at about USD 865 million in 2025 with projections to exceed USD 956 million in 2026. (bevnet.com) Creatine is being reformatted for mass appeal: Lemme launched Creatine Body‑Toning Gummies on Jan. 9, 2026, and GNC unveiled a next‑generation creatine lineup on Jan. 12, 2026; industry reports place the 2025 creatine/creatine‑supplement market in a wide band from roughly USD 640–1,370 million depending on the analyst. (prnewswire.com) Policy and clinical guidance are reshaping protein demand — the Dietary Guidelines for Americans 2025–2030 emphasizes prioritizing protein across meals, a point Nutritional Outlook connects to double‑digit category growth, and multiple medical societies have issued clinician‑facing nutrition guidance for patients using GLP‑1 therapies that highlights dietary protein strategies. (cdn.realfood.gov)
